Personal ECG technology company AliveCor has announced that they will be offering a QTc measurement service on their KardiaMobile 6L to medical professionals and patients in an effort to monitor the effects of COVID-19 and related medications.
QTc is a heart rate corrected interval which indicates the integrity of the heart's electrical recharging system, and can be impacted by many FDA-approved medications, including many being used to treat COVID-19. A prolonged QTc is potentially fatal, as it can lead to drug-induced sudden cardiac death.
AliveCor's KardiaMobile 6L is the only FDA-cleared six-lead personal ECG, and can be used both in and out of hospitals by doctors and patients. Data from the devices will go to an independent diagnostic testing facility to be interpreted and then returned to medical providers, providing QTc measurements to healthcare teams rapidly.
AliveCor has ever-growing IP in AI biotech space regarding non-invasive measurements of the heart. KardiaMobile 6L received FDA clearance last May and provides easy to understand data to users.
